First-Line Abemaciclib Effective in ER+ Breast Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2017-135
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Profile of Abemaciclib and Its Potential in the Treatment of Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2018English

Evaluating an ER Degrader for Breast Cancer

Cancer Discovery
Oncology
2015English

Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer

Cancer Discovery
Oncology
2016English

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

Genetically Engineered ER -Positive Breast Cancer Mouse Models

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2014English

Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Prohibitin Promotes Androgen Receptor Activation in ER-positive Breast Cancer

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2017English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy